Short Interest in Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Expands By 125.0%

On March 16th, 2025, it was reported that the Fidelity Disruptive Medicine ETF (NASDAQ:FMED) experienced a significant rise in short interest during February. According to the latest data up to February 28th, the total short interest reached 900 shares. This marks an impressive increase of 125.0% compared to the short interest recorded on February 13th, which was only 400 shares. Currently, approximately 0.0% of the fund's shares are sold short. Given the average daily trading volume of 5,700 shares, the short-interest ratio stands at 0.2 days, indicating a relatively short timeframe for covering these short positions.

Institutional Investment Activity

In recent trading activities, an institutional investor has notably increased its stake in the Fidelity Disruptive Medicine ETF. Specifically, Jane Street Group LLC raised its position in FMED shares by 200.4% during the third quarter, as documented in their latest 13F filing with the Securities and Exchange Commission. Following this acquisition, Jane Street Group LLC now holds 61,342 shares, having added an additional 40,924 shares to their portfolio. This investment represents about 2.92% of the total shares in the Fidelity Disruptive Medicine ETF, valued at approximately $1,613,000 at the conclusion of the most recent reporting period.

Stock Performance of Fidelity Disruptive Medicine ETF

As of Friday, FMED opened at $24.03. Over the past year, the stock has seen a low of $23.32 and a high of $26.79. The fifty-day simple moving average for the stock is $25.50, while the 200-day simple moving average is $25.70. The market capitalization of the Fidelity Disruptive Medicine ETF is noted at $50.46 million, with a price-to-earnings (P/E) ratio of 42.34 and a beta value of 0.94, indicating relatively stable performance in the market.

Dividend Announcement from Fidelity Disruptive Medicine ETF

Additionally, the company has recently announced a quarterly dividend. This dividend was distributed on Tuesday, December 24th, to shareholders on record as of Friday, December 20th. Each investor received a dividend of $0.112, which means an annualized dividend of $0.45, resulting in a yield of 1.86%. This increase marks a change from their prior quarterly dividend of $0.00.

Overview of Fidelity Disruptive Medicine ETF

The Fidelity Disruptive Medicine ETF (FMED) is classified as an exchange-traded fund focused primarily on health care equities. It operates as an actively managed fund, investing in firms engaged in innovative and disruptive advancements in the health care sector. The fund supports investments in both domestic and international securities. Since its launch on April 16, 2020, FMED has been managed by Fidelity.

Fidelity, Disruptive, Medicine, ETF, FMED